| Document Date: 2011-07-14 18:23:07
Open Document File Size: 44,12 KBShare Result on Facebook
City TOKYO / San Diego / / Company Vical Incorporated / Astellas Pharma Inc. / / Country Japan / United States / / Currency USD / / / Event Business Partnership / Funding / FDA Phase / Conference Call / / Facility Pacific Center Court / / / IndustryTerm regulatory and manufacturing expertise / immune systems / biotechnology / delivery technology / cancer therapeutics / treatment of serious or life-threatening diseases / pharmaceutical / Potential applications / biopharmaceutical products / manufacturing / pharmaceutical products / / MedicalCondition severe illness / cancer / metabolic diseases / herpes virus / certain infectious disease / CMV disease / diseases / infectious diseases / infection / / MedicalTreatment cancer therapeutics / organ transplant / / Organization Pacific Center Court / Securities and Exchange Commission / / Person Yoshihiko Hatanaka / Vijay Samant / / / Position global category leader / President and Chief Executive Officer / / Product TransVax / TransVax™ / United States / SOT / / ProvinceOrState California / / Technology neuroscience / DNA delivery technologies / immunotherapeutics / biotechnology / DNA delivery technology / biopharmaceutical products / biopharmaceutical / / URL www.vical.com / www.astellas.com/en / /
SocialTag |
10390 Pacific Center Court, San Diego, CA[removed]•646•1100, FAX: 858•646•1150 www.vical.com FOR IMMEDIATE RELEASE July 14, 2011